Exciva GmbH, a Heidelberg, Germany-based clinical biotech company developing a novel therapeutic compound for treating agitation/aggression in Alzheimer’s disease, closed a €9m ($10M) Series A financing.
The round was led by Andera Partners with participation from LBBW Venture Capital and Cure8.
The company intends to use the funds to develop Deraphan®, the lead compound, up to completion of Phase I.
Led by Francois Conquet, CEO, Exciva is a biopharmaceutical company applying a new scientific approach that fully integrates molecular, behavioral and chemistry technologies to address behavioral and psychological symptoms in Alzheimer’s disease and other dementias.
Its lead candidate (Deraphan®) combines two compounds which have separately demonstrated a safety profile as well as an efficient activity in patients living with behavioral conditions. The product has the potential to treat behavioral and psychological symptoms in Alzheimer disease patients.
The company’s board of directors is composed of:
- Raphaël Wisniewski (chairman) and Sofia Ioannidou, partners at Andera,
- Stefanie Wojciech, investment manager at LBBW Venture Capital GmbH, and
- Vikram Sudarsan, CEO of Engrail Therapeutics.